Clinical study protocol  
Doc ID:  Clinical study no:  Version:  Status:  Product : IND no:  
NA OXD01 -001 1.0 Final  OXD01  NA 
Issued by:  Date:  
David Capano  19 April 2021  
1 (48) 
Title: 
A randomized, open -label, parallel -group study to evaluate the efficacy of the digital therapeutic 
OXD01  (MODIA ‚Ñ¢) in combination with sublingual buprenorphine/naloxone for the t reatment of 
opioid use disorder  
Sponsor s‚Äô responsible medical officer  Michael Sumner, MB, BS MRCP (UK), MBA  
Orexo US, Inc.  
150 Headquarters Plaza 
East Tower , 5th Floor  
Morristown, NJ 07960  
CONFIDENTIAL:  This document is the property of Orexo US, Inc. No information contained herein may be 
disclosed without written approval from Orexo US.
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  2 (48)  
 
PROTOCOL SYNOPSIS  
Study title:  
A randomized, open -label, parallel- group study to evaluate the efficacy of the digital therapeutic 
OXD01  (MODIA ‚Ñ¢) in combination with sublingual buprenorphine/naloxone for the treatment of 
opioid use disorder.  
Study number : 
OXD01 -001 Product:  
OXD01  
Study phase:  
III Study population:  
Male and female subject s 
Number of subject s: 
510 enrolled  (approximately) , 400 randomized  Number of study centers:  
30-35 
Sponsor:  
Orexo US, Inc.  
Background/Rationale:  
Medication -assisted t reatment, the current standard  for opioid addiction,  is the use of medications  
in combination with counseling and behavioral t herapies  to provide a ‚Äúwhole -patient‚Äù approach to 
the treat ment of opioid use disorder (OUD). However, patients may not have optimal access to face -
to-face clinical behavioral health services. Digital therapeutics can help bridge the gap between 
accessible services and optimal treatment of OUD , the primary goal of which is to reduce the use of 
opioids . OXD01 is a device -based digital therapeutic , designed to offe r individuals diagnosed with 
OUD quality psychotherapy intervention based on cognitive behavioral therapy and motivational 
interviewing .  This study is being conducted to determine the value of OXD01 when combined with 
medication to change opioid use patte rns in subjects  with OUD.  
Objectives:  
Primary Objective:  
 
The primary objective of the study is to determine whether the combination of sublingual (SL) buprenorphine/naloxone (BUP/NAL)  standard of care (SOC) background therapy  and the digital 
therapeutic OXD01 is superior to SL BUP/NAL  alone  to reduce opioid use, as measured by the 
treatment success rate. Treatment success is defined as the subject having ‚â• 80% of urine drug 
tests negative for opioids  plus negative self -reports  for illicit opioid use (from the TLFB interview  at 
the same visit ) from Week 6 to Week 25.    
  
Secondary Objectives:  
 
Compare the treatment groups for the following outcomes:  
 
‚Ä¢ Cumulative response ‚Äì The cumulative response rate over a period from Week 6 to Week 25  of 
treatment. Response is defined as the presence of both a negative urine drug test for opioids and a self-report negative for illicit use of opioids at a study visit.  
 
‚Ä¢ Illicit opioid use - The cumulative response rate over a period from Week 6 to Week 25  of 
treatment with respect to the percentage of urine drug tests negative for opioids . 
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  3 (48)  
 
‚Ä¢ Self-reports of illicit opioid use - The cumulative response rate over a period from Week 6 to 
Week 25 of treatment with respect to the percentage of self -reports negative for illicit opioid 
use. 
 
‚Ä¢ Percentage of subjects abstinent - Abstinence  is defined as a subject having a urine drug test  
negative for opioids as well as self- reports negative for illicit opioid use at Week 25 . 
 
‚Ä¢ Proportion of subject s completing the study - A completer is defined as a participant who 
completed either the UDS or the self -report assessment at the Week 25  visit. 
 
‚Ä¢ Clinical global impression - This will be evaluated in two ways:  
 
o Scor e on the Clinical Global Impression -Improvement  scale at Week 12 and Week 25  
o Change from baseline in the Clinical Global Impression -Severity  score  at Week 12 and  
Week 25  
 
‚Ä¢ Opioid cravings - Change from baseline in the opioid craving score using the Opioid Craving 
Visual Analog Scale from  Week 4  to Week 25 . 
 
‚Ä¢ Illicit u se of non -opioid drugs of abuse - The cumulative percentage of subject s with urine drug 
tests negative for drugs  of abuse  (excluding opioids) plus  self- reports negative for use  of drugs 
of abuse  for the period from Week 6  to Week 25 . 
 
‚Ä¢ Number of hospitalizations , emergency department visits , and overdoses , and the ability  to 
resume work, school, or other productive activity  
 
‚Ä¢ Adverse events (AE). 
 
Treatments:  
‚Ä¢ SL BUP/NAL SOC background therapy  
‚Ä¢ SL BUP/NAL  + OXD01 digital therapy  for 15-30 minutes , 1-2 times per week  
 
Subjects in both groups will receive the assigned treatment for 24 weeks . Note: No investigational 
product will be administered as part of this study. Subjects in both groups may also be encouraged 
to participate in behavioral health therapies in accordance with the Investigator ‚Äôs standard of 
practice.  
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  4 (48)  
 
Methodology : 
This is an open -label, randomized, parallel- group multicenter study designed to evaluate the efficacy 
of the digital therapeutic OXD01 combined with SL BUP/NAL  SOC background therapy  compared to 
SL BUP/NAL alone to change opioid use pattern s in subject s with OUD.  
 
Approximately 510 opioid dependent adults  will be screened to randomize approximately 400 
subjects. The study will include a screening visit and a randomization visit, followed by 24 weeks of 
study treatment. Subjects will be schedule d for evaluation visits, which will include a UDS and a self-
report of drug use, weekly during the first four weeks of treatment, then every other week from 
weeks 5 through 12, then monthly through week 25. Subjects will also return to the site for only a 
UDS and a self- report of drug use each week between the evaluation visits.  
 
Statistical Considerations : 
Treatment success is defined as the subject having ‚â• 80% of urine drug tests negative for opioids plus ‚â• 80 % of self -reports negative for illicit opioid use (from the TLFB interview  at the same visit ) 
from Week 6 to Week 25 of the study.  Current literature suggests that the proportion of subjects likely to be successful by this measure while under treatment with the control agent may be approximate ly 12%.  [1] If OXD01 is effective in improving this percentage to 25%, approximately 200 
subjects will be required to receive each treatment to provide 90% power to detect such a difference at an ùõºùõº  = 0.05 level ( chi-squared t est).  Approximately 510 opioid dependent males and 
females will be screened to random ize approximately 400 subjects.   
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  5 (48)  
 
TABLE OF CONTENTS  
PROTOCOL SYNOPSIS  .......................................................................................................................................................... 2  
TABLE OF CONTENTS  ........................................................................................................................................................... 5  
LIST OF ABBREVIATIONS AND DEFINITION  OF TERMS  .......................................................................................................... 8  
1. INTRODUCTION  ........................................................................................................................................................... 9  
1.1 BACKGROUND  ................................................................................................................................................................ 9  
2. STUDY OBJECTVES AND ENDPOINTS.......................................................................................................................... 10 
2.1 PRIMARY OBJECTIVE  ...................................................................................................................................................... 10 
2.2 SECONDARY OBJECTIVES  ................................................................................................................................................. 10 
3. INVESTIGATIONAL PLAN  ............................................................................................................................................ 11 
3.1 SELECT ION OF STUDY DESIGN  .......................................................................................................................................... 15 
3.1.1  Overall Study Design  ........................................................................................................................................ 15 
3.1.2  Study Treatments ............................................................................................................................................. 15 
3.1.3  Subjects  ............................................................................................................................................................ 15 
4. SELECTION OF STUDY P OPULATION  .......................................................................................................................... 15 
4.1 INCLUSION CRITERIA  ...................................................................................................................................................... 15 
4.2 EXCLUSION CRITERIA  ...................................................................................................................................................... 16 
4.3 RESTRICTIONS  ............................................................................................................................................................... 17 
4.3.1  Concomitant Medication  ................................................................................................................................. 17 
4.4 WITHDRAWAL OF SUBJECTS  ............................................................................................................................................ 17 
4.5 SAFETY STOPPING CRITERIA FOR THE OVERALL STUDY  .......................................................................................................... 18 
5. STUDY TREATMENT  ................................................................................................................................................... 19 
5.1 TREATMENT REGIMEN  .................................................................................................................................................... 19 
5.2 SUBLINGUAL BUPRENORPHINE /NALOXONE MEDICATION ASSISTED TREATMENT  ....................................................................... 19 
5.2.1  Assessment of Compliance .............................................................................................................................. 19 
5.3 OXD01  ...................................................................................................................................................................... 19 
5.3.1  Initiation, Training ........................................................................................................................................... 19 
5.3.2  Assessment of Compliance .............................................................................................................................. 20 
6. STUDY PROCEDURES  ................................................................................................................................................. 20 
6.1 SUBJECT INFORMED CONSENT  ......................................................................................................................................... 20 
6.2 REMOTE VISIT PROCEDURES  ............................................................................................................................................ 20 
6.3 DEMOGRAPHIC DATA, MEDICAL HISTORY  .......................................................................................................................... 21 
6.4 OPIOID USE / DEPENDENCE  ............................................................................................................................................ 21 
6.5 PREVIOUS TREATMENTS FOR OPIOID USE DISORDER  ............................................................................................................ 21 
6.6 CONCOMITANT MEDICATIONS  ......................................................................................................................................... 21 
6.7 PHYSICAL EXAMINATION  ................................................................................................................................................. 21 
6.8 VITAL SIGNS MEASUREMENTS  ......................................................................................................................................... 22 
6.9 DRUG SCREEN  .............................................................................................................................................................. 22 
6.10 QUANTITY -FREQUENCY INDEX  ......................................................................................................................................... 22 
6.11 TIMELINE FOLLOWBACK METHOD ‚Äì DRUG AND ALCOHOL USE............................................................................................... 22 
6.12 REVIEW STUDY RESTRICTIONS  .......................................................................................................................................... 23 
6.13 RANDOMIZATION AND ALLOCATION TO TREATMENT , SUBJECT IDENTIFICATION NUMBER  ............................................................ 23 
6.14 OPIOID CRAVING VISUAL ANALOG SCALE ........................................................................................................................... 23 
6.15 QUICK INVENTORY OF DEPRESSION SYMPTOMS , SELF-REPORT  ............................................................................................... 23 
6.16 REVIEW BEHAVIORAL HEALTH THERAPIES  .......................................................................................................................... 23 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  6 (48)  
 
6.17 CLINICAL GLOBAL IMPRESSION  ......................................................................................................................................... 23 
6.18 END OF STUDY INTERVIEW  .............................................................................................................................................. 24 
7. ADVERSE EVENTS  ...................................................................................................................................................... 24 
7.1 DEFINITIONS  ................................................................................................................................................................. 24 
7.1.1  Adverse Event .................................................................................................................................................. 24 
7.1.2  Adverse Reaction ............................................................................................................................................. 25 
7.1.3  Unanticipated Adverse Device Effect  ............................................................................................................... 25 
7.1.4  Serious Adverse Event  ...................................................................................................................................... 25 
7.2 ADVERSE EVENT REPORTING PERIOD  ................................................................................................................................ 25 
7.3 COLLECTION OF ADVERSE EVENT DATA .............................................................................................................................. 25 
7.4 RECORDING OF ADVERSE EVENTS  ..................................................................................................................................... 26 
7.5 SERIOUS ADVERSE EVENT REPORTING / UNANTICIPATED ADVERSE DEVICE EFFECTS ‚àí PROCEDURES FOR INVESTIGATORS  ................... 27 
7.5.1  Initial Reports ................................................................................................................................................... 27 
7.5.2  Follow -up Reports  ............................................................................................................................................ 27 
7.6 REPORT ING RESPONSIBILITIES  .......................................................................................................................................... 28 
7.7 PREGNANCY  ................................................................................................................................................................. 28 
8. MEDICAL SAFETY  ....................................................................................................................................................... 28 
8.1 EXPECTED SIDE EFFECTS  ................................................................................................................................................. 28 
8.1.1  OXD01  .............................................................................................................................................................. 28 
9. STUDY DOCUMENTS, REC ORD KEEPING, SOURCE DATA AND CASE REPORT  FORMS  ................................................. 28 
9.1 PROTOCOL AND INFORMED CONSENT FORM ...................................................................................................................... 28 
9.2 PROTOCOL AND INFORMED CONSENT CHANGES  .................................................................................................................. 29 
9.3 RECORDS  ..................................................................................................................................................................... 29 
9.4 SOURCE DATA AND CASE REPORT FORMS  .......................................................................................................................... 29 
10. DATA MANAGEMENT  ............................................................................................................................................ 29 
11. STATISTICAL CONSIDERATIONS AND DETERMINA TION OF SAMPLE SIZE  ............................................................... 30 
11.1 STUDY POPULATIONS  ..................................................................................................................................................... 30 
11.2 STUDY DISPOSITION  ....................................................................................................................................................... 30 
11.3 PRIMARY OBJECTIVE  ...................................................................................................................................................... 30 
11.4 SECON DARY OBJECTIVES  ................................................................................................................................................. 31 
11.5 SAFETY ANALYSES  .......................................................................................................................................................... 32 
11.6 DETERMINATION OF SAMPLE SIZE ..................................................................................................................................... 32 
12. STUDY REPORT  ...................................................................................................................................................... 32 
13. QUALITY CONTROL AND QUALITY ASSU RANCE  ..................................................................................................... 32 
13.1 QUALITY CONTROL  ........................................................................................................................................................ 32 
13.1.1  Quality Control Procedures  .............................................................................................................................. 32 
13.1.2  Monitoring  ....................................................................................................................................................... 32 
13.2 QUALITY ASSURANCE AUDITS AND INSPECTIONS  .................................................................................................................. 33 
13.3 TRAINING OF STAFF ....................................................................................................................................................... 33 
14. ETHICAL CONSIDERATIONS  ................................................................................................................................... 33 
14.1 RISK-BENEFIT ASSESSMENT  ............................................................................................................................................. 33 
14.2 ETHICAL CONDUCT OF THE STUDY  ..................................................................................................................................... 33 
14.2.1  Voluntariness, Subject Information, and Consent  ........................................................................................... 33 
14.2.2  Subject Safety  .................................................................................................................................................. 34 
14.2.3  Subject Data Protection  ................................................................................................................................... 34 
14.3 ETHICAL REVIEW  ........................................................................................................................................................... 34 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  7 (48)  
 
15. REFERENCES  .......................................................................................................................................................... 35 
APPENDIX A: PROTOC OL SIGNATURES  ............................................................................................................................... 36 
APPENDIX B: DIAGNOSTIC AND STATISTICAL MANUAL OF MEN TAL DISORDERS ‚Äì 5TH EDITION ‚Äì CRITERIA FOR MODERAT E 
OR SEVERE OP IOID USE DISORDER  .................................................................................................................................... 39 
APPENDIX C: QUICK INVENTORY OF D EPRESSION SYMPTOMS, SELF -REPORT  .................................................................... 40 
APPENDIX D: TIMELINE FOLLOWBACK METHOD ‚Äì DRUGS AND ALCOHOL  ......................................................................... 44 
APPENDIX E: TIMELINE FOLLOWBACK METHOD ‚Äì DRUGS  ................................................................................................. 46 
APPENDIX F: VISUAL A NALOG SCALE ‚Äì OPIOID CRAVINGS  ................................................................................................. 48 
List of Figures 
FIGURE 1: STUDY SCHEMA  ............................................................................................................................................................... 12 
 List of Tables T
ABLE 1: SCHEDULE OF EVENTS : SCREENING , WEEKS 1-12..................................................................................................................... 13 
TABLE 2: SCHEDULE OF EVENTS : SCREENING , WEEKS 13-25, EARLY TERMINATION  ..................................................................................... 14 
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  8 (48)  
 
LIST OF ABBREVIATION S AND DEFINITION OF TERMS  
Abbreviation/term  Definition  
AE Adverse event (s) 
BUP/NAL  Buprenorphine/naloxone  
CFR Code of Federal Regulations  
CGI-S/I Clinical global impression ‚Äì severity/improvement  
CRF Case report form  
CYP Cytochrome P450  
ECG Electrocardiography  
DSM  Diagnostic and Statistical Manual of Mental Disorders   
eCRF  Electronic case report form  
FDA United States Food and Drug Administration  
GCP Good Clinical Practice s 
ICF Informed consent  form  
ICH International Conference on  Harmonisation  
IRB Institutional review board  
IRS Interactive response system  
MAT  Medication -assisted treatment  
OUD  Opioid use disorder  
QFI Quantity -Frequency Index  
QIDS -SR Quick Inventory of Depression Symptoms,  Self-Report  
SAE Serious adverse event  
SL Sublingual  
SOC Standard of care  
SUSAR  Suspected unexpected serious adverse reaction  
TLFB  Timeline followback  
UADE  Unanticipated adverse device effect  
UDS  Urine drug screen  
VAS Visual analog scale  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  9 (48)  
 
1. INTRODUCTION  
1.1 Background  
 
In 2017, 70,237 drug overdose deaths occurred in the United States. The age-adjusted rate of overdose deaths increased significantly by 9.6% from 2016 (19.8 per 100,000) to 2017 (21.7 per 100,000).   Opioids , 
primarily synthetic opioids other than methadone , are currently the main driver of drug overdose deaths 
and were implicated in 47,600 overdose deaths in 2017 (67.8% of all drug overdose deaths).  [2] 
 Effective and available treatment is the gateway to reducing the morbidity and mortality associated with 
drug addiction. Medication -assisted t reatment (MAT) , the current standard for opioid addiction,  is the use 
of medications, in combination with counseli ng and behavioral therapies, to provide a ‚Äúwhole -patient‚Äù 
approach to the treat ment of opioid use disorder (OUD) . Research shows that MAT can successfully treat 
opioid use disorder ( OUD) , and for some people can help sustain recovery.  [3] 
 Successful MAT implementation requires the availability of varying levels and types of care in a range of 
settings, although all of the necessary services may not be available to all patients . Patients appropriate 
for outpatient care require access to office -based buprenorphine prescribing (or opioid treatment 
program s that provide methadone) and clinical behavior al health services . However, the National Center 
for Health Workforce Analysis estimates that between 40 million and 45 million individuals (roughly 20 percent  of the U.S. 2013 population) may have needed but did not receive behavioral health care in  2013. 
The National Center completed a projection of US supply and demand for behavioral h ealth practitioners 
in 2025 and identified s ix provider types that are tracking for shortage  of more than 10,000 full-time 
equivalents: psychiatrists; clinical, counseling, and school psychologists; substance abuse and behavioral 
disorder counselors; menta l health and substance abuse social workers; mental health counselors; school 
counselors.  [4]  
 Clearly one challenge for healthcare providers working on the front of the current opioid crisis is to 
improve the availability and access to treatment, particularly  behavioral health services. However, based 
on the National Center estimate , trained behavioral health professionals will not join the workforce in 
adequate numbers to meet the demand for services.  The evidence is that man y patients who require 
behavioral health services are not getting access, or chose not to engage in face- to-face therapy. N ew 
modes of service delivery are necessary  to close the gap between patients and the treatment required for 
recovery from addiction.   Digital therapeutics , an innovative  new category of mobile medical applications that help treat diseases by 
modifying patient behavior and providing remote monitoring to improve long- term health outcomes , are 
poised to improve the quality of healthcare across a broad spectrum of the market . Digital therapeutics 
implement treatment programs tailored to specific ailments, and the early evidence is that these digital 
health programs, often combined with human coaching/interaction, can effectively close service gaps and make a significant difference in health outcomes.  In addition, digital health programs can be tailored and 
optimized for individual patients and delivered at scale via mobile  devices , which can conceivably be 
transformative to the healthcare marketplace . With precise regimes and daily monitoring, digital 
therapeutics offer valuable data t hat can provide doctors insight  into patient behavior and create 
feedback/optimization loops for individual patients. Enabling patients to take greater control over 
managing their chronic illnesses and preventing disease progression could yield substantial  cost savings 
througho ut the entire healthcare system, and evidence suggests that treatment adherence may be 
improved by new technologies.  [5] 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  10 (48) 
 
 
OXD01 is a n individualized  device -based digital therapeutic designed to be an adjunctive treatment tool 
for OUD. OXD01 is designed to offer individuals diagnosed with OUD quality psychotherapy intervent ion 
based on cognitive  behavioral therapy and motivational interviewing , implemented through  a smart 
application with artificial intelligence.  
 OXD01 has not been studied in patients with OUD  receiving standard of care  (SOC)  MAT with sublingual 
buprenorphine /naloxone . The current study is being conducted to determine the value of OXD01 to 
reduce opioid use when combined with medication to treat OUD.   
2. STUDY OBJECT VES AND ENDPOINTS  
2.1 Primary Objective  
 
The primary objective of the study is to determine whether  the combination of sublingual (SL) 
buprenorphine/naloxone (BUP/NAL)  SOC background therapy  and the digital therapeutic OXD01 is 
superior to SL BUP/NAL alone to reduce opioid use, as measured by the treatment success rate. 
Treatment success is defined as t he subject having ‚â• 80% of urine drug tests negative for opioids plus  
negative  self- reports for illicit opioid use ( based on  the timeline followback  [TLFB ] interview at the same 
visit) from Week 6 to Week 25 .   
2.2 Secondary Objectives  
 
The secondary objective s are to compare the treatment group s for the following outcomes:  
 
‚Ä¢ Cumulative response ‚Äì The cumulative response rate from Week 6 to Week 25  of treatment. 
Response is defined as the presence of both a negative urine drug test  for opioids  and a negative self-
report  for illicit use of opioids  at a s tudy  visit.  
 
‚Ä¢ Illicit u se of opioids - The cumulative response rate from Week 6 to Week 25  of treatment with 
respect to the percentage of urine drug test s negative for opioids . 
 
‚Ä¢ Self-report of illicit  use of  opioid s - The cumulative response rate from Week 6 to Week 25  of 
treatment with respect to the percentage of negative self- reports for illicit  use of  opioid s. 
 
‚Ä¢ Percentage of subjects abstinent - Abstinence  is defined as a subject having a urine drug test  negative 
for opioids as well as negative self-reports for illicit  use of  opioid s at Week 25 . 
 
‚Ä¢ Proportion of subjects completing the study - A completer is defined as a participant who completed 
either the UDS or the self -report assessment at the Week 25  visit. 
 
‚Ä¢ Clinical global impression - Will be evaluated by : 
 
o Scor e on the Clinical Global Impression -Improvement (CGI -I) scale at Week 12 and Week 25  
o Change from baseline in the Clinical Global Impression -Severity  (CGI -S) score  at Week 12 and  
Week 25  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  11 (48) 
 
‚Ä¢ Opioid cravings - Change from baseline in the opioid craving score using the opioid craving visual 
analog scale ( VAS) from  Week 4  to Week 25 . 
 
‚Ä¢ Use of illicit  non-opioid  drugs  of abuse  - The cumulative percentage of subjects  with urine drug test s 
negative for illicit drugs  of abuse  (excluding opioids) plus  negative self- reports for illicit drug use from 
Week 6  to Week 25 . 
 
‚Ä¢ Number of hospitalizations, emergency department visits, and overdoses, and the ability to resume 
work, school, or other productive activity . 
 
‚Ä¢ Adverse events  (AE) 
 
3. INVESTIGATIONAL PLAN  
 
This is an open -label, randomized, parallel- group multicenter study designed to evaluate the efficacy of the 
digital therapeutic OXD01 combined with SL BUP/NAL  SOC background therapy compared to  SL BUP/NAL  alone 
in the treatment of subject s with OUD.  
 
Approximately 510 opioid dependent adults  will be screened to randomize approximately 400 subjects. Current 
literature suggests that the proportion of subjects likely to be successful by this measure wh ile under treatment 
with the control agent may be approximately 12%.  [1] If OXD01 is effective in improving this percentage to 25%, 
approximately 200 subjects will be required to receive each treatment to provide 90% power to d etect such a 
difference at an ùõºùõº  = 0.05 level (Fisher‚Äôs Exact Test).   
 
The study will include a screening visit  and a randomization visit , followed by  24 weeks of study treatment 
during which the subject will participate in  24 study visits (11 evaluation visits plus 13 visits to perform  only  a 
urine drug screen ( UDS) and collect a subject self- report of drug use , Figure 1 ).  
 The screening visit will identify opioid dependent  adults seeking MAT for moderate -to-severe OUD.  Subject s 
who have received MAT for OUD within 14 days or those with a diagnosis of moderate to severe substance use 
disorder involving  psychoactive substances other than opioids  will be  excluded.  
 Eligible subjects will be randomized to one of two treatment groups in a 1:1 ratio:  
 
‚Ä¢ SL BUP/NAL  SOC background therapy  
‚Ä¢ SL BUP/NAL  + OXD01 digital therapy   
 Subjects in both groups  will receive the assigned treatment for 24 weeks.  Note: No investigational product will 
be administered as part of this study.  Subjects in both groups may also be encouraged to participate in 
behavioral health therapies in accordance with the Investigator ‚Äôs standard of practice.  
 On study Day 1 all subjects will have been  stabilized on SL  BUP/NAL . Subjects randomized to BUP/NAL pl us 
OXD01 digital therapy will use  the OXD01 application  as non -pharmacologic treatment for their OUD. OXD01 is a 
web -based software platform  that can be used on a mobile phone, tablet, or computer with a compatible 
browser such as Google Chrome, Mozilla Firefox, Internet Explorer, or Safari.  
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  12 (48) 
 
Subjects will be scheduled for evaluation visits, which will include a UDS and a self -report of drug use , weekly 
during the first four weeks of treatment, every other week from weeks 5 through 12, and monthly through 24 
weeks. Subjects will also return to the site for a UDS and a self- report  of drug use each week between the 
evaluation visits.  
 
Figure 1. Study Schema  
 
  
 
 
  
Screening  
 
Weekly Evaluation 
Visits* 
  
R 
Monthly Evaluation Visits*  
  
SL BUP/NAL  
+ 
OXD01  
  
SL BUP/NAL:  
+ 
OXD01  
 
Every Other Week  
Evaluation Visits*  
  
3 Weeks  
BUP/NAL 
Stabilization  
8 Weeks  
 12 Weeks  
 4 Weeks 
SL BUP/ NAL  
SL BUP/NAL  
+ 
OXD01  
  
SL BUP/N AL  
 SL BUP/N AL  
R ‚Äì randomization; SL BUP/NAL ‚Äì sublingual buprenorphine/naloxone  
*Evaluation visits: Week s 2-5, 7, 9, 11, 13, 17, 21, 25   
*Urine drug screen/drug use interview only: Weeks 6, 8, 10, 12, 14 -16, 18 -20, 22 -24 
 
Day 
-21 to 1  
Day 1 
 Week 5  
 Week 13  
 Week 25  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  13 (48) 
 
 
Table 1. Schedule of Events : Screening, Weeks 1 -12 
Evaluation  Screening  Treatment  
Day  
-21 to 1  Week 1  
Day 1  Week  
2/3/4  
Day 
8/15/22  Week 5  
Day 29  Week 6  
Day 36  Week 7  
Day 43  Week 8  
Day 50  Week 9  
Day 57  Week 10  
Day 64  Week 11  
Day 71  Week 12  
Day 78  
Window  NA NA ¬± 1 Day  ¬± 1 Day  ¬± 1 Day  ¬± 1 Day  ¬± 1 Day  ¬± 1 Day  ¬± 1 Day  ¬± 1 Day  ¬± 1 Day  
Informed consent  X           
Demographics  X           
Inclusion/exclusion criteria review  X X          
Medical history  X           
Opioid use history  X           
Confirm diagnosis - OUD1 X           
Previous treatments for OUD  X           
Concomitant medications2 X X          
Physical examination  X           
Vital signs  X X          
Urine drug screen  X X X X X X X X X X X 
QFI  X          
TLFB interview  ‚Äì drugs and alcohol   X          
TLFB interview ‚Äì drugs    X X X X X X X X X 
Review study restrictions with subject  X X X X  X  X  X  
Randomization - IRS3  X          
OXD01  ‚Äì subject training3  X          
Opioid craving VAS   X  X    X    
QIDS -SR X           
CGI-S  X          
CGI-I            
Review behavioral health therapies    X X  X  X  X  
MAT compliance assessment/counseling    X X  X  X  X  
OXD01 compliance assessment/counseling    X X  X  X  X  
Adverse Events   X X X X X X X X X X 
OUD ‚Äì opioid use disorder; QFI ‚Äì Quantity -Frequency Index; TLFB ‚Äì timeline followback  method; IRS ‚Äì interactive response system; MAT ‚Äì medication -
assisted treatment; VAS ‚Äì visual analog scale; QIDS -SR ‚Äì Quick Inventory of Depression Symptoms, Self -Report;  CGI-S/I ‚Äì clinical global impression 
severity/improvement  
1. The subject must meet the criteria for moderate or severe opioid use disorder based on DSM -V (Appendix B ).  
2. Concomitant medication s ongoing on Day 1 will be recorded.   
3. As soon as the subject is clinically stable on SL BUP/NAL  with physical withdrawal symptoms managed , and the subject able to fully participate in 
OXD01 training,  but no greater than 14 days  from the first dose of SL BUP/NAL induction.  
 
 
  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  14 (48) 
 
Table 2 . Schedule of Events : Weeks 13- 25, Early Termination  
Evaluation  Treatment  
Early 
Termination  Week 13  
Day 85  Week  
14/15/16  
Day 
92/99/106  Week 17  
Day 113  Week  
18/19/20  
Day 
120/127/ 134  Week 21  
Day 141  Week  
22/23/24  
Day 
148/155/162  Week 25  
Day 169  
Window  ¬± 1 Day  ¬± 1 Day  ¬± 1 Day  ¬± 1 Day  ¬± 1 Day  ¬± 1 Days  ¬± 1 Day  
Informed consent          
Demographics          
Inclusion/exclusion criteria review          
Medical history          
Opioid use history          
Confirm diagnosis - OUD1         
Previous treatments for OUD          
Concomitant medications2         
Physical examination          
Vital signs          
Urine drug screen  X X X X X X X X 
QFI       X X 
TLFB interview ‚Äì drugs and alcohol        X X 
TLFB interview ‚Äì drugs  X X X X X X   
Review study restrictions with subject  X  X  X    
Randomization ‚Äì IRS3         
OXD01  ‚Äì subject training3         
Opioid craving VAS  X  X  X  X X 
QIDS -SR       X X 
CGI-S X      X X 
CGI-I X      X X 
Review behavioral health therapies  X  X  X  X X 
MAT compliance assessment/counseling  X  X  X  X X 
OXD01 compliance assessment/counseling  X  X  X  X X 
End of study interview        X X 
Adverse Events  X X X X X X X X 
OUD ‚Äì opioid use disorder; QFI ‚Äì Quantity -Frequency Index; TLFB ‚Äì timeline followback  method; IRS ‚Äì interactive response system; MAT ‚Äì medication -
assisted treatment; VAS ‚Äì visual analog scale; QIDS -SR ‚Äì Quick Inventory of Depression Symptoms, Self -Report; CGI-S/I ‚Äì clinical global impression 
severity/improvement  
1. The subject must meet the criteria for moderate or severe opioid use disorder based on DSM -V (Appendix B ).  
2. Concomitant medication s ongoing on Day 1 will be recorded.   
3. As soon as the subject is clinically stable on SL BUP/NAL  with physical withdrawal symptoms managed, and the subject able to fully participate in 
OXD01 training,  but no greater than 14 days  from the first dose of SL BUP/NAL induction.  
  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  15 (48) 
 
3.1 Selection of Study Design  
3.1.1 Overall Study Design  
 
This is a prospective, open -label, randomized, parallel-group superiority study designed to determine whether 
the efficacy of OXD01 combined with SL BUP/NAL  SOC background therapy  is superior to BUP/NAL alone in the 
treatment of subject s with OUD. The study is comprised of a screening visit and a randomization visit, followed 
by 24 weeks of study treatment and 24 study visits (11 evaluation visits plus 13 visits to perform a UDS and 
collect a subject self -report of drug use ). 
 A randomized, parallel- group design is selected to  assure an adequately controlled study. An open -label design 
is necessary because there is not a placebo or sham validated for the OXD01 digital therapeutic. 
3.1.2 Study Treatments  
 
On study Day 1, subjects  stabilized on SL BUP/NAL  SOC background therapy  will be randomized to SL BUP/NAL 
alone, or to SL BUP/NAL plus the OXD01 digital therapeutic. A stabilized subject  will have completed SL BUP/NAL 
induction, with physical withdrawal symptoms reduced so the subject  is able to fulling participate in OXD01 
training , if randomized to that treatment group. Induction with SL BUP/NAL and titration to a maintenance dose 
that suppresses withdrawal signs and symptoms is  described in the product information under Dosage and 
Administration  and can be implemented  in accordance with the Investigator ‚Äôs standard of practice.  Note: No 
investigational product will be administered as part of this study.  
 
Subjects randomized to SL BUP/NAL plus OXD01 will be trained to use OXD01 on Day 1 as directed in the OXD01 Clinician User Guide  and will begin to access the therapeutic counseling modules  for 15-30 minutes,  1-2 times 
per week as instructed.  Randomization and OXD01 training should be conducted as soon as the subject is 
clinically stable , with physical withdrawal symptoms managed and the subject able to fully  participate in the 
process , but no greater than 14 days  from the first dose of SL BUP/NAL induction .  
 Subjects in both groups will use  the assigned treatment for 24 weeks.  
3.1.3 Subject s 
 Approximately 400 opioid dependent adults , seeking MAT for OUD, will be randomized.  An e ligible subject  must 
be in generally good health, seeking MAT treatment for moderate or severe OUD (absent a moderate to severe  
use disorder for other psychoactive substances) and ha s not received MAT for OUD wi thin 14 days prior to 
screening.  
4. SELECTION OF STUDY POPULATION  
4.1 Inclusion Criteria  
 
A subject must meet the following criteria to qualify for the study.  
 1. Male or female  18 ‚Äì 65 years of age  at the screening visit , fluent in English and able to read, comprehend, 
and willingly sign the informed consent form  (ICF) . 
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  16 (48) 
 
2. Voluntarily seeking treatment for OUD.  
 
3. In the judgment of the Investigator  has the appropriate hearing, vision, manual dexterity, ability to 
understand instructions, and ability to use and understand internet -based  applications.  
 
4. Currently meets the criteria for moderate or severe opioid use disorder according to Diagnostic and  
Statistical Manual of Mental Disorders  (DSM) -V (Appendix B) . 
 
5.  Has a p ositive UDS  for opioids  at screening  that is consistent with their drug use history .  
 
6. In good health as determined by lack of clinically significant abnormalities in health asses sments performed 
at screening.  
 
7. Agrees not to take any buprenorphine products other than those prescribed by the Investigator during 
participation in the study , and agrees to use  OXD01 as directed if randomized to that treatment group.   
 
8. Completed SL BUP/NAL induction, with physical withdrawal symptoms reduced so the subject is able to 
fulling participate in OXD01 training, if randomized to that treatment group, and is no greater than 14 
days  from the first dose of SL BUP/NAL induction .  
4.2 Exclusion Criteria  
 
A subject  who meets any of the following criteria will not qualify for the study.  
 1. Unwilling or unable to comply with the requirements of the protocol or are in a situation or condition that, in the opinion of an Investigator , may interfere with participation in the study  (e.g., does not have 
reliable internet access).  
 
2. History of allergy or sensitivity to naloxone, buprenorphine  or other opioids , or history of any drug 
hypersensitivity or intolerance which, in the opinion of an Inv estigator, would compromise the safety of 
the subject . 
 
3. Used an investigational drug within 30 days or 5 half-lives (whichever is greater) prior to randomization.  
4. Received prescribed medication -assisted treatment  with buprenorphine, methadone, or naltrexone  for 
opioid use disorder within 14 days prior to screening. 
 
5. Past or present diseases  that, judged by an Investigator and based on available medical history/records, 
may jeopardize the safety of the subject  or impact  the validity of the study results . 
 
6. Tongue piercing, or piercings in the mouth or oral deformities that may affect sublingual absorption , in 
the opinion of an Investigator.   
7. Hospitalization for a psychiatric disorder in the past 30 days , not including inpatient treatment for drug 
rehabilitation.   
 
8. Schizophrenia, or other serious mental illness defined as a mental, behavioral, or emotional disorder 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  17 (48) 
 
resulting i n serious functional impairment  which substantially interferes with or limits participation in the 
study . 
 
9. A Quick Inventory of Depression Symptoms - Self-Report (QIDS -SR, Appendix C) score ‚â• 16 (severe 
depression ) or a rating of 2 or 3 for question 12 (Thoughts of Death or Suicide ) at screening. 
   
10. A current diagnosis, other than opioid use disorder, requiring chronic opioid treatment.  
 
11. Chronic pain that is unremitting or unstable . 
 
12. Current DSM -V diagnosis of moderate to severe substance use disorder for psychoactive substances other 
than opioids, caffeine , marijuana, or nicotine.  
 
13. Requires current use of medications that are strong inhibitors or inducers of cytochrome P450  (CYP)  3A4 
(Section 4.3.1) . 
 
14. Any pending legal action that could affect  participation or compliance in the trial.  
 
15. Is an employee of the Investigator  or the trial site, with direct involvement in the proposed trial or other 
trials under the direction of the Investigator  or trial site, or is a family member of the Investigator  or an 
employee.  
4.3 Restrictions  
4.3.1 Concomitant M edication 
 
The following medications are prohibited during the study:  
 
‚Ä¢ CYP3A4 i nhibitors - macrolide antibiotics (e.g., erythromycin), azole -antifungal agents (e.g. 
ketoconazo le); the non-nucleoside reverse transcriptase inh ibitor antiretroviral delavirdine ; the 
protease inhibitor antiretrovirals atazanavir and ritonavir 
 
‚Ä¢ CYP3A4 i nducers - rifampin, carbamazepine, phenytoin ; the non-nucleoside reverse t ranscriptase 
inhibitor antiretrovirals efavirenz, nevirapine, and etravirine  
 
‚Ä¢ Monoamine oxidase inhibitors   
4.4 Withdrawal of Subject s 
 
Every subject  has the right to refuse participation in the study at any time and for any reason. A subject ‚Äôs 
participation must therefore be terminated immediately upon his/her request.  
 
An Investigator or the sponsor may withdraw a subject  from the study to protect the health of a subject . A 
subject  will be withdrawn from the study for the following safety -related reasons:  
 
‚Ä¢ Subject  experiences a  serious adverse event ( SAE) assessed as related to the study treatment by an 
Investigator or Orexo . 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  18 (48) 
 
 
‚Ä¢ Subject  experiences other unacceptable AE(s) assessed as related to the study treatment by an 
Investigator. 
 
‚Ä¢ Subject requires a prohibited concomitant medication.  
 
‚Ä¢ Subject  displays hypersensitivity reactions to BUP/NAL . 
 
‚Ä¢ Other significant subject  safety issue as assessed by an Investigator or Orexo . 
 
An Investigator  will make every attempt to explain the reason(s) for discontinuation and to document this in the 
appropriate sections of the case report forms  (CRFs) and in the source documentation, using the following as a 
guide:  
 
‚Ä¢ Subject  requests discontinuation.  
 
‚Ä¢ Subject  is non -compliant, defined as refusal or inability to adhere to the study procedures.  
 
‚Ä¢ Treatment failure, as defined by an Investigator , using any and all information including subject 
interview.  
 
‚Ä¢ Unacceptable or intolerable treatment- related AEs.  
 
‚Ä¢ Any illness or circumstance that would adversely affect the study procedures or outcome measures.  
 
‚Ä¢ At the request of Orexo, regulatory agencies, or institutional review board (IRB).  
 
‚Ä¢ Subject  is lost to follow -up. 
 
The final record  will include reasons for withdrawal, AEs, and any necessary medical treatment.  
 
Subject s who drop out  of the study after randomization will not be replaced.  
4.5 Safety Stopping Criteria for the O verall Study  
 
The clinical study will be stopped if the  sponsor determines  the safety risks for study subject s exceed the 
anticipated risks, as described in the study protocol.  The following occurrences (non -exclusive) will trigger a re -
evaluation of the risk assessment for the study, which could lead to a stop of the overall study : 
 
‚Ä¢ Occurrence of an unexpected SAE in the study assessed as related to OXD01 by an Investigator or 
sponsor ( serious unanticipated adverse device effect as defined in Sections 7.1.3 and 7.1.4. 
 
‚Ä¢ Occurrences of SAEs, assessed as related to OXD01,  at a higher rate or severity than expected as 
assessed by an Investigator  or the sponsor. 
 
‚Ä¢ Occurrence of other significant subject  risks in the study . 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  19 (48) 
 
5. STUDY TREATMENT  
5.1 Treatment Regimen  
 
Eligible subjects will be randomized to one of two treatment groups in a 1:1 ratio:  
 
‚Ä¢ SL BUP/NAL  SOC background therapy  
‚Ä¢ SL BUP/NAL  + OXD01 digital therapy   
 Subjects in both groups will receive the assigned treatment for 24 weeks. Note: No investigational product will 
be administered as part of this study.  Subjects in both groups may also be encouraged to participate in 
behavioral health therapies in accordance with the Investigator ‚Äôs standard of practice.  
 Prior to study Day 1 all subjec ts will have completed SL BUP/NAL induction, with physical withdrawal symptoms 
reduced so the subject is able to fulling participate in OXD01 training, if randomized to that treatment group.  
Study Day 1 should occur as soon as the subject is clinically stable , with physical withdrawal symptoms managed 
and the subject able to fully participate in the process , but no greater than 14 days  from the first dose of SL 
BUP/NAL induction . 
 
Subjects randomized to SL BUP/NAL plus the OXD01 digital therapeutic will be trained to use OXD01 on Day 1 as 
directe d in the OXD01 Clinician User Guide  and will begin to access the therapeutic counseling modules for 15-
30 minutes, 1 -2 times per week as instructed.  
5.2 Sublingual Buprenorphine/Naloxone  Medication Assisted Treatment  
 The subject will obtain buprenorphine /naloxone sublingual tablets from a retail pharmacy with a prescription 
from the Investigator. Prior to study Day 1 subjects will initiate SL BUP/NAL , complete induction, and have 
physical withdrawal symptoms reduced so the subject is able to full y participate in OXD01 training, if 
randomized to that treatment group. Subjects will take the prescribed dose daily of SL BUP/NAL from Day 1 
through Day 169 as directed by the Investigator. 
5.2.1 Assessment of Compliance  
 Dosing instructions will be reviewed and subjects will be interviewed to assess t reatment compliance at the 
following Visits: Weeks 2 -5, 7, 9, 11, 13, 17, 21, and 25. Any l apses in treatment compliance will be addressed 
with the subject during these visits.  
5.3 OXD0 1 
5.3.1 Initiation , Training  
 The Investigator/designee  will receive instruction on initiating and training subjects to use OX D01 (see OXD01 
Clinician Guide)  prior to enrolling the first subject at the site.  
 On study Day 1 subjects randomized to SL BUP/NAL plus the OXD01 digital therapeutic will be trained by the Investigator or designee to use OXD01 ( see OXD01 Clinician Guide  and Patient Guide ) and will begin to access 
the therapeutic counseling modules for 15 -30 minutes, 1 -2 times per week as instructed. OXD01 training should 
be conducted as soon as the subject is clinically stable , with physical withdrawal symptoms managed and the 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  20 (48) 
 
subject able to fully  participate in the process , but no greater than 14 days  from the first d ose of SL BUP/NAL 
induction . Training should include a discussion of the key concepts of recovery and working with OXD01  (OXD01 
Clinician Guide , Getting  Subjects Started with MODIA ‚Äì Training and Registration ).  
5.3.2 Assessment of Compliance  
 
Subjects must continue to use OXD01 for 15-30 minutes , 1-2 times per week from Day 1  (Section 5.3.1) through 
Day 169. Treatment compliance will be assessed through subject interviews at the following Visits: Weeks 2 -5, 7, 
9, 11, 13, 17, 21, and 25. Lapses in compliance with the recommended use of OXD01 will be addressed with the 
subject. The Investigator or designee will also record  the following  OXD01  usage information: typical number of 
sessions per week and duration of each session, and progress completing the chats  since the previous 
evaluation . The Investigator or designee will reinforce the key concepts of recovery and working with OXD01 
(OXD01 Clinician Guide , Maintaining Motivation and Monitoring Compliance ).  
6. STUDY PROCEDURES  
6.1 Subject  Informed Consent  
 
An IC F approved by the IRB, that includes all of the relevant elements currently required by federal regulations (21 
Code of Federal Regulations [ CFR] Part 50 ) and applicable  state and local regulations , will be provided to each 
prospective study s ubject  at screening , before enrol lment into the study. The  requirements for participation, the  
type and method of study tests to be administered, any potential or possible hazards, and the subject 's right to 
withdraw from the study at any time will be explained to the subject s by an Investigator  or designee. Once an 
Investigator  or designee is assured that an individual candidate understands the implications of participating in this 
study, the subj ect will be asked to give consent by signing and dating in the appropriate areas of the IC F. An 
Investigator  or designee will also sign and date the form. A copy of the IC F will be provided to the subject .   
 
The subject ‚Äôs signed and dated informed consent  must be obtained before conducting any study specific 
procedures, including the following:  
 
‚Ä¢ Withholding or discontinuation of concomitant medical treatment for the purpose of the study  
‚Ä¢ Physical examination for the purpose of the study  
6.2 Remote Visit Procedures  
 
In the Guidance on Conduct of Clinical Trials of Medical Products during COVID -19 Public Health Emergency  
Guidance for Industry, Investigators, and Institutional Review Boards1 the Food and Drug Administration ( FDA) 
recognizes that the COVID -19 public health emergency may  impact the conduct of clinical trials. When 
circumstances such as quarantines, site closures, and travel limitations  lead to difficulties in meeting protocol-
specified procedures, sites may use telemedicine to perform procedure s or collect endpoint evaluations, with 
                                                           
 
 
 
1 https://www.fda.gov/media/136238/download  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  21 (48) 
 
the exception of collecting a urine sample for the drug screen. Procedures conducted through telemedicine 
must be appropriately identified  and the circumstance explained  in the subject record .  
6.3 Demographic Data, Medical History  
 Relevant medical and social history will be documented during the screening visit to assess eligibility.  
 The following demographic data will be collected:  
 
‚Ä¢ Date of birth  
‚Ä¢ Gender  
‚Ä¢ Ethnic origin  
6.4 Opioid Use / Dependence  
 Opioid use over the past 30 days and the duration of OUD will be documented  at screening. The criteria for 
moderate or severe opioid use disorder according to DSM -V will be verified at screening ( Appendix B). 
6.5 Previous Treatments for Opioid Use Disorder  
 A treatment history , including counseling,  over the previous 2 years for OUD  will be recorded at screening.  
6.6 Concomitant Medications  
 Concomitant medications will be reviewed at screening, and subjects who require chronic treatment with strong 
inhibitors or inducers of CYP3A4 w ill not be eligible for the study (Section 4.3.1).  
 
Medications that are ongoing on study Day 1 will be recorded. Additions, deletions, or changes to concomitant 
medications after Day 1 will not be recorded.  
6.7 Physical Examination  
 A physical examination  will be performed by the Investigator  at screening . The following areas will be included : 
 
‚Ä¢ General inspection  
‚Ä¢ Neck veins / pulses  
‚Ä¢ Oral cavity / teeth (for assessment of abnormalities possibly affecting sublingual absorption) 
‚Ä¢ Palpation of precordium and auscultation of the heart  
‚Ä¢ Auscultation of chest  
‚Ä¢ Abdominal examination (liver, spleen, and lower abdomen)  
‚Ä¢ Peripheral pulses (radial and foot)  
‚Ä¢ Assessment of reflexes (biceps, knee, and ankle)  
 Any abnormalities will be recorded.   
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  22 (48) 
 
6.8 Vital Signs Measurements  
 
Vital signs (body temperature, respiratory rate, heart  rate, and blood pressure) will be measured at screening  and 
on study Day 1 . Vital signs will be measured after resting in the supine position for at least 5 minutes.  
6.9 Drug S creen  
 A urine sample will be  taken at screening , study Day 1, and at weekly visits  during the study to test for the 
following drugs of abuse : amphetamines, barbiturates, b enzodiazepines , cocaine  metabolite , marijuana 
metabolite , methadone , opiate s, phencyclidine, propoxyphene , and buprenorphine.  
 Precautions should be taken to prevent manipulation of the urine sample by the subject .  
6.10 Quantity -Frequency Index  
 The Quantity -Frequency Index (QFI) is a self -assessment of the frequency and quantity of alcohol consumption 
over the previous 30 days. The QFI is comprised of the following two questions:  
 
During the past 30 days:  
 1. How often do you have a drink contain ing alcohol?  
 (0) Never  
(1) Monthly or less  
(2) 2 to 4 times a month  
(3) 2 to 3 times a week  
(4) 4 or more times a week  
 2. How many drinks containing alcohol do you have on a typical day when you are drinking?  
 
(0) 1 or 2  
(1) 3 or 4  
(2) 5 or 6  
(3) 7, 8, or 9  
(4) 10 or more  
 
The QFI will be completed on study Day 1 and at the visit on Week 25.  
6.11 Timeline Followb ack Method ‚Äì Drug and Alcohol  Use 
 The TLFB is a self-assessment used to document recent use of opioid s, other illicit drug s of abuse, and alcohol . A 
TLFB assessment will be completed on study Day 1, and at weekly visits while on study treatment. Subjects will 
be asked to estimate both drug and alcohol use during the 7 days prior to the study visit on Day 1 and Week 25. 
Subjects will be asked to estim ate only drug use during the 7 days prior to the study visit on Weeks 2-24. The 
TLFB is a closed Yes or No question of drug or alcohol use  (Appendix D, E).  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  23 (48) 
 
6.12 Review Study Restrictions  
 
Study  restrictions  (Section 4.3) will be reviewed with the subject  at study screening, and at the visits on Week s 
1-5, 7, 9, 11, 13, 17, and 21.  
6.13 Randomization and A llocation to T reatment , Subject Identification Number  
 Eligible subjects will be randomized on Day 1 through an IRT  system (separate instructions will be provided).  
 Each subject  will be identified by a unique randomization number  assigned by the IRS  system on Day 1. Prior to 
randomization, subject s will be identified by a screening number , assigned  when the subject  signs the ICF. 
6.14 Opioid Craving Visual Analog Scale  
 Cravings for opioids will be assessed by the subject through the use of a  VAS, where 0 mm represents  ‚Äúno 
cravings‚Äù and 100 mm represents ‚Äúthe most intensive craving I have ever had.‚Äù The baseline  craving VAS 
assessment will be collected on study Day 1 an d at the visit on  Weeks 5 , 9, 13,  17, 21 and 25  (Appendix F).  
6.15 Quick Inventory of Depression Symptoms, Self -Report  
 
Symptoms of depression will be assessed by the subject using the QIDS -SR (Appendix C) at screening and at  the 
visit on  Week 25.  An overall score ‚â• 16 (severe depression) or a  rating of 2 or 3 for question 12 (Thoughts of 
Death or Suicide) at screening will exclude the subject from the study.  
6.16 Review Behavioral Health Therapies  
 
Participation in behavioral health therapies  since the previous visit , including 12 -step programs, will be recorded  
at the visits on Weeks 1 -5, 7, 9, 11, 13, 17, and 21.   
6.17 Clinical Global Impression  
 Clinic al Global Impression (Severity) - Severity of opioid dependence will be assessed by the Investigator on 
study Day 1 and at the visit on  Week 13 and  Week 25 using the following assessment scale:  
 
Considering your total clinical experience with this particular population, how mentally ill is the subject at this time?  
 
0 = Not assessed  
1 = Normal, not at all ill 
2 = Borderline ill 3 = Mildly ill 4 = Moderately ill  
5 = Markedly ill  
6 = Severely ill  
7 = Among the most extremely ill subjects  
  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  24 (48) 
 
 
Clinical Global Impression (Improvement)  ‚Äì Improvement  in severity of opioid dependence from baseline (study 
Day 1) will be assessed by the Investigator at the visit on Week 13 and Week 25 using the following assessment 
scale:  
 
Rate total improvement whether or not, in your judgement, it is due entirely to drug treatment. Compared 
to his or her condition at admission to the project, how much has the subject changed?  
 
0 = Not assessed  
1 = Very much improved  
2 = Much improved  
3 = Minimally improved  
4 = No change  
5 = Minimally worse  
6 = Much worse  
7 = Very much worse  
6.18 End of Study Interview  
 The following information will be obtained from the subject at the visit on Week 25 , addressing the time from 
Day 1 through Day 169 (or early termination):  
 
‚Ä¢ Number of emergency department visits  
‚Ä¢ Number of hospitalizations  
‚Ä¢ Number of overdoses  
‚Ä¢ Able to resume work, school, or other productive activity ( Yes, N o, or No Change)  
 
7. ADVERSE EVENTS  
7.1 Definitions  
7.1.1 Adverse Event  
 
An adverse event  is any untoward medical occurrence in a subject  or clinical trial subject  caused by, or 
associated with a device  and which does not necessarily have to have a causal relationship with the device . An 
AE can therefore be any unfavorable  and unintended sign, symptom, or disease tempora lly associated with the 
use of the device, whether or not considered related to the intended use of the device . 
 Pre-existing conditions will not be regarded as AEs if the condition follows a normal course of recovery, unless it 
worsens after exposure to the device . Medical procedures will not be  regarded as AEs, but the cause of the 
procedure may be.  
  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  25 (48) 
 
7.1.2 Adverse Reaction  
 
An adverse reaction is all noxious  and unintended response s in a subject  using a medical device . The phrase 
related to a medical device means that a causal relationship between a device and an adverse event is at  least 
a reasonable possibility;  i.e., the relationship cannot be ruled out.  
7.1.3 Unanticipated Adverse Device Effect  
 
An u nanticipated adverse device effect  (UADE) is any serious adverse effect on health or safety, any life -
threatening problem or death caused by, or associated with a device, if that effect, problem, or death was not 
previously identified in nature, severity, or degree of incidence in the device ; or any other unanticipated serious 
problem associated with a device that relates to the safety or welfare of subjects.  
7.1.4 Serious Adverse Event  
 An SAE is an AE that:  
 
‚Ä¢ results in death  
‚Ä¢ is life threatening  
‚Ä¢ requires hospitalization  or prolongation of existing hosp italization  
‚Ä¢ results in persistent or significant disability/incapacity  
‚Ä¢ is a congenital anomaly/birth defect  
‚Ä¢ is another important medical event (e.g. , convulsions not leading to hospitalization ) 
 Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalization  but may jeop ardize  the subject ‚Äôs health or may require intervention to prevent one of 
the other outcomes listed in the definitions above. These AEs should also usually be considered as  serious . 
 SAEs will only be considered when there is an underlying AE. For example, a hospitalization  due to a pre -existing 
condition which is not due to an aggravation of the condition after exposure to any study treatment will not be 
considered to be an SAE.  
7.2 Adver se Event Reporting Period  
 The AE reporting period will start  after signing the informed consent form and will end at discharge from the 
study . 
7.3 Collection of Adverse Event Data 
 The subject s will be monitored throughout the study for any AE s, including abnormal, clinically significant, 
laboratory values, clinically significant findings at physical examinations, vital signs measurements or electrocardiogram ( ECG) measurements, spontaneous reports by study subject s and observations by the study 
personnel . AEs will be collected through both solicited and unsolicited means and subsequently coded in tabular 
form using the Medical Dictionary for Regulatory Activities Terminology ( MedDRA ) Version 14.1 or later AE  
dictionary.  The subject s will be encouraged to report signs, symptoms, and any changes in health to the clinic staff. 
Severity of each AE will be determined by an Investigator  based on observation and questioning of the subject . 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  26 (48) 
 
7.4 Recording of A dverse Events  
 
All AEs should be recorded in the CRF s. Although an AE can initially be acknowledged by anyone in the study 
team, an Investigator will always be responsible for reporting and assessments of AEs. All AEs should be 
reported separately (i.e . one record per event). Reporting of AEs are event based, (i.e. , an ongoing event will not 
be closed until resolved or at the end of study). At least the following will be recorded for each AE:  
 Description of adverse event: Adverse event description should be provided in English. Diagnosis is to be 
preferred over symptoms. If no diagnosis could be made, each symptom will be reported as a separate AE. 
Abbreviations should be avoided. Descri ptive  words should be used for ongoing conditions as applicable (e.g. 
‚Äúexacerbation of herpes genitalis‚Äù, ‚Äúworsening of eczema‚Äù etc.).  
 Serious adverse event:  Yes or no (definition of SAE in section 7.1.4). If Yes, a n SAE Report Form needs to be 
completed.  
 Maximum intensity: Maximum intensity of the AE during the complete course of the event should be recorded 
in accordance with the following definitions:  
 
‚Ä¢ Mild ‚Äì Awareness of sign and symptoms but easily tolerated  
‚Ä¢ Moderate ‚Äì Discomfort sufficient to cause interference with normal activities  
‚Ä¢ Severe ‚Äì Incapacitating, with inability to perform normal activities  
 Duration: The duration of the AE will be recorded by start and stop date and time.  
 
Relatedness to medical device  (causality):
 Relatedness to the medical device will be assessed by an 
Investigator  according to the below categories.    
 
‚Ä¢ Not related : A causal relationship between the medical device  and the AE is assessed as not possible 
(e.g. due to onset in relation to use of the device  or that another cause of the AE has been identified )  
‚Ä¢ Related : A causal relationship between the medical device  and the AE is assessed as at least possible  
 
Actions taken: Actions taken in relation to the AE  with respect to use of the medical device , should be recorded 
as: 
 
‚Ä¢ Use of the medical device withdrawn  
‚Ä¢ Use of the medical device interrupted  
‚Ä¢ Use of the medical device is reduced  
‚Ä¢ Use of the medical device is increased  
‚Ä¢ Use of the medical device not changed  
‚Ä¢ Not applicable  
‚Ä¢ Unknown  
 Any medication given to treat the AE will be record ed separately on the concomitant medication list of the CRF s. 
  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  27 (48) 
 
 
Outcome: The outcome of the AE should be recorded.  
 
‚Ä¢ Recovered/Resolved  
‚Ä¢ Recovering/Resolving  
‚Ä¢ Not recovered/Not resolved  
‚Ä¢ Recovered/Resolved with sequelae  
‚Ä¢ Fatal 
‚Ä¢ Unknown ‚Äì lost to follow -up 
7.5 Serious Adverse Event Reporting/ Unanticipated Adverse Device Effects ‚àí Procedures for Investigators  
7.5.1 Initial Reports  
 
All SAEs /UADEs  occurring from the time of informed consent until discharge from the study must be reported to 
Medpace Clinical Safety with in 24 hours of the knowledge of the occurrence. After discharge from the study , any 
SAE/UADE  that the Investigator considers related to study drug must be reported to the Medpace Clinical Safety 
or the Sponsor/designee.  
 To report the SAE/UADEs , complete t he form electronically in the electronic data capture (EDC) system for the 
study. When the form is completed, Medpace Safety personnel will be notified electronically by the EDC system and will retrieve the form. If the event meets serious criteria and it is not possible to access the EDC system, send an email to Medpace Safety at medpace -safetynotification@medpace.com or call the Medpace SAE 
reporting line (phone number listed below), and fax/email the completed paper form to Medpace (contact information listed in Section 7.5.2 ) within 24 hours of awareness. When the EDC system becomes available, the 
SAE information must be entered as soon as possible.  
7.5.2 Follow -up Reports 
 
The Investigator must continue to follow the patient until the SAE /UADE  has subsided or  until the condition 
becomes chronic in nature, stabilizes (in the case of persistent impairment), or the patient dies.  
 
Within 24 hours of receipt of follow -up information, the Investigator must update the form electronically in the 
EDC system for the stu dy and submit any supporting documentation ( e.g., patient discharge summary or 
autopsy reports) to Medpace Clinical Safety via fax or e -mail. If it is not possible to access the EDC system, refer 
to the procedures outlined above for initial reporting of SA Es/UADEs. 
 Safety Contact Information: Medpace Clinical Safety  
Medpace SAE reporting line:  
Telephone: +1 -800-730-5779, dial 3 or +1- 513-579-9911, dial 3  
Fax: +1 -866-336-5320 or +1 -513-570-5196 
E-mail: medpace -safetynotification@medpace.com
 
 The Investigator is primarily responsible for ensuring proper care of study subject s. Medical queries with regards 
to the management of subject s with SAEs and AEs may  also be addressed to the medical monitor at Orexo . 
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  28 (48) 
 
7.6 Reporting Responsibilities  
 
Orexo will report UADEs to the FDA. Medpace will be responsible for submitting reports of UADEs to sites and 
Central IRBs according to applicable regulations and stipulated timelines. Sites will be responsible for reporting 
to local IRBs as required.   
 In the event an SAE is reported as related to BUP/NAL (SOC background therapy), Medpace will forward this information to the manufacturer for postmarketing reporting to the FDA as re quired.  
7.7 Pregnancy  
 A confirmed pregnancy does not require withdrawal of the subject from the study. The Investigator  should 
consider the risk -benefit analysis for the individual subject and either continue or discontinue BUP/NAL 
treatment based on their clinical judgement.  
 The outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth or congenital 
abnormality) must be followed up and documented even after the subject  was discontinued from the trial.  
 All events of congenital abnormalities/birth defects are SAEs. Spontaneous miscarriages should also be reported 
and handled as SAEs.  
 
8. MEDICAL SAFETY  
8.1 Expected Side Effects  
8.1.1 OXD01  
 
Since OXD01 is a non- systemic therapy for OUD, the likelihood of adverse events is low. However, the following 
emotions may occur when using the application:  
 
‚Ä¢ Disappointment if there is no benefit  
‚Ä¢ Distress when presented with particular topics.  
‚Ä¢ Frustratio n, or other distressing emotions, if the content is found to be confusing, overwhelming, or 
unsuitable.   
 
Subjects should be directed to contact the Investigator if any of these feelings become significant.  
9. STUDY DOCUMENTS, REC ORD KEEPING, SOURCE DATA AND CASE REPORT FORMS  
9.1 Protocol and Informed Consent F orm 
 The study will be performed in accordance with this study protocol. The Investigator  indicated on Form FDA 1572 
will act as the Principal Investigator. Copies of the signed Form FDA 1572 and protocol will be provided to the 
sponsor.  
 
Based on the study protocol, Medpace  will develop a written ICF that includes all of the relevant elements  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  29 (48) 
 
currently required by FDA (21 CFR part 50) or state regulations (see section 6.1 ). 
 
The protocol and the ICF must be approved by the relevant IRB  prior to st udy conduct per 21 CFR part 56.  
9.2 Protocol and Informed Consent Changes  
 Changes to the protocol or the IC F will be implemented as amendments to the original document and must be 
approved by the applicable IRB prior to implementation. Protocol amendments are normally agreed between Orexo and the Investigator  prior to finalization, h owever, urgent changes needed to protect the safety of study 
subject s should be implemented directly and the sponsor and IRB should then be notified as soon as possible. 
Copies of all protocol and IC F amendments/revisions, along with letters noting IRB approval, will be submitted to 
the sponsor. Any addendum , amendment, or revision that substantially alters the study design or increases 
potential risk to the subject  requires the subject 's consent to continue in the study.  
9.3 Records  
 Adequate records will be maintained for the study as required by International Conference on  Harmonisation  
(ICH) Good Clinical Practices ( GCP). This will include volunteer medical records, CRFs, laboratory reports, work 
sheets, signed ICFs, drug dispensing records, AE  reports, information regarding volunteers‚Äô discontinuation and 
similar.  Following completion of the study, Medpace will supply the sponsor with originals of the CRFs  (or a copy if 
electronic CRFs are used) and copies of  laboratory reports and ECGs . CRF copies  and original laboratory reports 
and ECGs will be retained for archiving by Medpace . No study related e ssential documents , records or data  
should be  destroyed without prior written authorization by Orexo.  
9.4 Source Data and Case Report Forms  
 Subject s will be identified by screening number prior to  randomization  and a subject  number after the first dose 
of study medication. Source documents will be used to record all study -related data. 
 
Source document entries will be used to complete CRFs. A set of CRFs will be completed for each subject  
randomized  in the study. All data and CRFs will be reviewed, evaluated, and signed by the Investigator, as 
required. An electronic CRF  (eCRF)  system  will be used in this study.  
 
All changes to the eCRF data will be traced by an audit trail incorporated in the eCRF system.  
10. DATA MANAGEMENT  
 Each investigative site will maintain source documentation and enter subject  data into the CRF s as accurately as 
possible and will respond to any reported discrepancies rapidly.  
 Electronic case report forms are accessed at the investigative sites . This electronic data capture system is 
validated and compliant with US Title 21 CFR  Part 11. Each pers on involved with the study will have an individual 
identification code and password that allows for record traceability. Thus, the system, and subsequently any investigative reviews, can identify coordinators, Investigator s, and individuals who have entere d or modified 
records, as well as the time and date of any modifications. There is an internal quality review audit of the data 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  30 (48) 
 
and additional reviews by a clinical monitor.  
 
Each CRF is presented as an electronic copy, allowing data entry by clinical unit personnel, who can add and edit data, add new subject s, identify and resolve discrepancies, and view records. This system provides immediate 
direct data transfer to the database, as well as immediate detection of discrepancies, enabling clinical unit 
personnel to resolve and manage discrepancies in a timely manner.  
 
Paper copies of the CRFs and other database reports may be printed and signed by the I nvestigator . This system 
provides clinical unit personnel, monitors, and reviewers with access to hardcopy audits, discrepancy reviews, and Investigator comment information.  
11. STATISTICAL CONSIDERATIONS AND DETERMINATION OF  SAMPLE SIZE  
 Prior to  the database lock, a detailed statistical analysis plan will be completed and placed on file.  The statistical 
analysis plan will contain a more comprehensive explanation of the methodology used in the statistical analyses than that described below.   The statistical analysis plan will also contain the rules and data handling 
conventions used to perform the analyses, and the procedure used for accounting for missing data.  
 In general, summary tabulations will display the number of observations, mean, standard deviation, median, minimum, maximum, and appropriate percentiles for continuous variables, and the number and percentage by 
category for categorical data.  Summaries will present data by treatment arm and overall.  The data listings will include all available efficacy and safety data.  
11.1 Study  Populations  
 The primary efficacy analyses will be based on full analysis population that consists of all  randomized  subjects .   
The safety analyses will be based on safety population that is consistent of all randomized subject s. 
11.2 Study Dis position  
 Demographic and baseline characteristics  for the enrolled subject s will be summarized separately by treatment 
assignment .  Summary statistics will be used to describe these two groups.  No hypotheses will be tested  with 
respe ct to baseline characteristics.  
11.3 Primary Objective  
 
The primary objective of the study is to determine whether the combination of SL BUP/NAL SOC background 
therapy and the digital therapeutic OXD01 is superior to SL BUP/NAL alone to reduce opioid use, as measured by 
the treatment success rate. Treatment success is defined as the subject having ‚â• 80% of urine drug test s 
negative for opioids  plus ‚â• 80 % of  self- reports negative for illicit opioid use (from the TLFB interview  at the same 
visit) from Week 6  to Week 25 .  Each subject will be evaluated as a success or failure for this metric and the 
proportion of subject s in each group demonstrating ‚â• 80% of urine drug test s negative for opioids  plus negative  
self- reports for illicit opioid use (from the TLFB interview) will be tested using chi -squared  test.  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  31 (48) 
 
11.4 Secondary Objectives  
 
The secondary objectives are to determine whether the combination of SL  BUP/NAL  SOC background therapy 
and the digital therapeutic OXD01 is superior to SL BUP/NAL alone  with respect to the following variables.  Note 
that the secondary objectives are listed in priority order for potential gatekeeping statistical approaches.  
 
‚Ä¢ Cumulative response ‚Äì The cumulative response rate from Week 6 to Week 25  of treatment. Response is 
defined as the presence of both a negative urine drug test for opioids and a self -report negative for illicit use 
of opioids at a study visit.   
 
To compare the two treatment groups with respect to their cumulative distribution functions of the 
proportion of subject s responding, the Kolmogorov- Smirnoff methodology will be used.  
 
‚Ä¢ Illicit u se of opioids - The cumulative response rate from Week 6 to Week 25  of treatment with respect to 
the percentage of urine drug test s negative for opioids will be the primary metric for this variable.  To 
compare the two treatment groups with respect to their cumulative distribution functions of the proportion of subjects responding, the Kolmogorov -Smirnoff methodology will be used.  
 
‚Ä¢ Self-reports of illicit  use of  opioid s - The cumulative response rate from Week 6 to Week 25  of treatment 
with respect to the percentage of self -reports negative for illicit  use of  opioid s will be the primary metric for 
this variable.  To compare the two treatment groups with respect to their cumulative distribution functions 
of the proportion of subject s responding with self -reports negative for illicit opioid use , the Kolmogorov-
Smirnoff methodology will be used.  
 
‚Ä¢ Percentage of subjects abstinent - Abstinence  is defined as a subject having urine drug test s negative for 
opioids as well as self- reports negative for illicit use of opioid s at Week 25 .  Each subject  will be scored as 
abstinent or non-abstinent and the groups will be compared using a chi -squared  test.  
 
‚Ä¢ Proportion of subjects  completing the study - A completer is defined as a participant who completed either 
the UDS or the self -report assessment at the Week 25  visit.   The groups will be compared with respect to the 
proportion of completers using a chi -squared  test.  
 
‚Ä¢ Clinical global impression - This w ill be evaluated in two ways.  
 
o Scor e on the CGI -I scale at week 12 and Week 25  
o Change from baseline in the Clinical Global Impression -Severity score at Week 12 and Week 25  
 
CGI scores will be evaluated using general linear model methodology or non -parametric analogs.  
 
‚Ä¢ Opioid cravings  - Change  from baseline in the opioid craving score using the Opioid Craving VAS from Week 
4 to Week 25 . Opioid Craving  scores will be evaluated using general linear model methodology or non -
parametric analogs. 
 
‚Ä¢ Use of illicit non-opioid drugs of abuse -   The cumulative percentage of subjects with  urine drug test s 
negative for illicit drugs  of abuse  (excluding opioids) plus  self- reports negative for illicit drug use for the 
period from Week 6 to Week 25  will be evaluated using the Kolmogorov -Smirnoff methodology.  
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  32 (48) 
 
‚Ä¢ Number of hospitalizations, emergency department visits, and overdoses, and the ability to resume work, 
school, or other productive activity . 
11.5 Safety Analyses  
 Adverse events - Safety will be assessed by recording and monitoring adverse events.   Rates of adverse events 
will be summarized overall and by organ system class, preferred  term, severity , and suspected relationship to 
the medical device by treatment assignment .   
11.6 Determination of Sample Size  
 Treatment success is defined as the subject having ‚â• 80% of urine drug tests negative for opioids plus ‚â• 80 % of 
self- reports negative for illicit opioid use (from the TLFB interview  at the same visit) from Week 6 to Week 25 of 
the study.  Current literature suggests that the proportion of subjects likely to be successful by this measure while under treatment with the control agent may be approximately 12%.  [1] If OXD01 is effective in improving 
this percentage to 25%, approximately 200 subjects will be required to receive each treatment to provide 90% power to detect such a difference at an ùõºùõº  = 0.05 level (Fisher‚Äôs Exact Test).  Approximately 510 opioid dependent 
males and females will be screened to randomize approximately 400 subjects.      
12. STUDY REPORT  
The clinical, statistical and bioanalytical report will be generated by  Medpace . 
Medpace will integrate the different parts of the report so that it is in an ICH E3 and electronic common 
technical document  compliant format suitable for sponsor submission to Health Agencies.  
13. QUALITY CONTROL AND QUALITY ASSURANCE  
13.1 Quality Control  
13.1.1  Quality Control Procedures  
 Appropriate Quality Control measures in critical processes will be employed for the conduct of the study , in data 
management, in the statistical analysis and in the report writing, to ensure that data reported from the study is true and r eliable.  
13.1.2  Monitoring  
 The study will be adequately monitored in accordance with ICH Harmonised Tripartite Guideline for GCP . 
Monitoring is performed to ensure that the study is conducted in accordance with the study protocol, applicable laws and regulations and ICH GCP. The clinical site will facilitate monitoring of the study by cooperating with the monitor and will make documentation, source data and staff available to the monitor.  
 The clinical monitor, as a representative of the sponsor, will follow the study closely. In doing so, the monitor 
will visit the principal Investigator and sub -Investigator  at the clinical site  at periodic intervals, in addition to 
maintaining necessary contact through telephone, e -mail, and letter. The monitor will maintain current personal 
knowledge of the study through observation, review of study records and source documentation, and discuss ion 
of the conduct of the study with the principal Investigator , sub -Investigator , or clinical unit staff.  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  33 (48) 
 
13.2 Quality Assurance Audits and I nspections  
Orexo  (or designee) may conduct audits at the clinical site at their discretion . Audits may include, but are not 
limited to, study procedures  including the informed consent process, study drug accountability, regulatory 
aspects of study conduct, source documentation and CRF transcription for compliance with GCP . A Quality 
Assurance  Statement of items audited  will be provided in the final report. Sponsor audits, when applicable, will 
be documented by an audit certificate . 
 
The trial site may also be subject to inspections /audits  by a regulatory authority or an IRB. The Investigator  is 
required to inform Orexo immediately of any inspection requested.  
 
The clinical site  will facilitate auditing and inspections by cooperating with auditors/inspectors and will make 
documentation, source data and staff available as needed.  
13.3 Training of S taff 
 
Before inclusion of subject s Orexo and/or the monitor will perform a trial initiation visit to inform and train 
relevant trial staff. All Investigators and staff carrying out observations of primary or other major variables involved in the trial should provide curriculum  vitae. The principal Investigator will keep a list of all personnel 
involved in the trial together with their function and trial relat ed duties delegated. The Investigator will ensure 
that appropriate trial related training is given to the staff involved in the trial, and that new information of 
relevance to the performance of this trial is appropriately forwarded.  
14. ETHICAL CONSIDERATIO NS 
14.1 Risk-Benefit Assessment  
 
Opioid dependence is associated with decreased quality of life and increased morbidity and mortality. 
Medication -assisted treatment, a combination of an opioid agonist or partial agonist with psychosocial 
intervention, has been shown to be more effective than detoxification and abstinence in reducing the frequency and quantity of opioid use as well as the risk of overdose, improving social functioning, and decreasing criminal 
activity.
24  
 
The current study is not expected to provi de data which will alter the safety profile of buprenorphine  used for 
MAT. 
14.2 Ethical Conduct of the Study  
 The trial will be performed in accordance with the recommendations guiding physicians in biomedical research 
involving human subject s that were adopted  in 1964 by the 18th World Medical Assembly, in Helsinki, Finland, 
with later revisions and in accordance with ICH GCP . It is the duty of the Investigator  to protect the life, health, 
privacy and dignity of the subject s. 
14.2.1  Voluntariness, Subject  Information, and Consent  
 
The Investigator will ensure that the subject  is given full and adequate oral and written information about the 
nature, purpose, possible risks and benefits of this study and that he voluntarily consents to participate in the 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  34 (48) 
 
study in writing according to section 6.1 . Subject s will have the right to withdraw from the study at any time 
without consequences on their continued treatment, and must be pro perly informed of these rights.  
14.2.2  Subject  Safety  
 
The Investigator‚Äôs duty is first and foremost to safeguard the life and health of study subject s. When in conflict, 
considerations related to the well- being of the human subject  should take precedence ove r the performance of 
the study.  
14.2.3  Subject  Data Protection  
 All information obtained during the conduct of the study with respect to the subject s‚Äô state of health will be 
regarded as confidential in accordance with national data legislations. This is detailed in th e written information 
provided to the subject  and an agreement for disclosure of any such information will be obtained in writing and 
is included in both copies of the volunteer ICF  signed by the subject . 
 In order to maintain anonymity, subject s will be identified by a special subject  number in lieu of the subject ‚Äôs 
name in all subject  data handling outside the clinical unit. The code list connecting the subject  numbers to the 
identity of the subject s will be kept by the Investigator  and will on ly be disclosed to external parties for the 
purpose of quality control, quality assurance , and IRB  or regulatory inspections.  
14.3 Ethical Review 
 The study protocol, ICF, subject information,  Investigator 's brochure ( or package insert as applicable), and any 
specific advertising will be submitted to an independent IRB  for review before the start of the study. A form 
signed by the chairman or designee of the  IRB noting approvals  of the study  must be obtained before enrollment 
of any subject . This notification of the board's approval along with a description by profession and gender of the 
board's composition will be provided to the sponsor. The IRB will be informed of any serious AE s occurring 
during the study.  
 Substant ial amendments to the study protocol and/or subject  information/ ICF should be submitted to the IRB 
and may not be implemented until approved, unless immediate actions are required to protect the safety of study participants.  
  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  35 (48) 
 
15. REFERENCES  
 
[1]  F. Dang, "Clinical Review: Application Number 209819Orig1s000 (Sublocade (Buprenorphine) extended -
release injection)," Center for Drug Evaluation and Research, Beltsville, 2017.  
[2]  Centers for Disease Control and Prevention, "Drug Overdose Deaths," US Department of Health and Human 
Services, 27 June 2019. [Online]. Available: https://www.cdc.gov/drugoverdose/data/statedeaths.html. 
[Accessed 15 January 2020].  
[3]  "Medication and Counseling Treatment," Substance Abuse and Mental Health Servi ces Administration, 7 
May 2019. [Online]. Available: https://www.samhsa.gov/medication -assisted -
treatment/treatment#medications -used -in-mat. [Accessed 15 January 2020].  
[4]  Health Resources and Services Administration, "National Projections of Supply and  Demand for Selected 
Behavioral Health Practitioners: 2013 -2025," National Center for Health Workforce Analysis, Rockville, 2016.  
[5]  B. Clough and L. Casey, "Technological adjuncts to increase adherence to therapy: a review," Clin Psychol 
Rev, vol. 31, pp. 697 -710, 2011.  
[6]  R. Rudd, N. Aleshire, J. Zibbell and R. Gladden, "Increases in Drug and Opioid Overdose Deaths ‚Äî United 
States, 2000 ‚Äì2014," Morbidity and Mortality Weekly Report, 1 January 2016. [Online]. Available: 
https://www.cdc.gov/mmwr/previ ew/mmwrhtml/mm6450a3.htm?s_cid=mm6450a3_w. [Accessed 15 
January 2020].  
 
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  38 (48) 
 
Protocol Signature ‚Äì Principal Investigator  
 
Document  
Doc ID:  Clinical study no:  Version:  Status:  Product : IND no:  
NA OXD01 -001 1.0 Final  OXD01  NA 
Title:  
A randomized, open -label, parallel -group study to evaluate the efficacy of the digital therapeutic OXD01  
(MODIA ‚Ñ¢) in combination with sublingual buprenorphine/naloxone for the treatment of opioid use disorder  
Issued by:  Date:  
David Capano  19 April 2021  
  I agree to the terms of this study protocol. I will conduct the study in accordance with the procedures specified 
in the study protocol,  the ethical principles in the Declaration of Helsinki, ICH Good Clinical Practice and all 
other applicable regulatory requirements.  
  
 
Signature  
  
Date:  ________________  
Signature:  _________________________________________  
 
Address:  
  
   
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  39 (48) 
 
APPENDIX B: DIAGNOSTIC AND STATI STICAL MANUAL OF MENTAL DISORDERS ‚Äì 5TH EDITION  ‚Äì 
CRITERIA FOR MODERAT E OR SEVERE OPIOID U SE DISORDER 
 
Opioid Use Disorder requires at least 2 criteria be met within a 12 month period:  
 1. Opioids are often taken in larger amounts or over a longer period of time than intended.   
 2. There is a persistent desire or unsuccessful efforts to cut down or control opioid use.   
 3. A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or recover from its 
ef
fects.    
 4. Craving, or a strong desire to use opioids.   
 5. Recurrent opioid use resulting in failure to fulfill major role obligations at work, school or home.   
 6. Continued opioid use despite having persistent or recur re nt social or interpersonal problems caused or 
exacerbated by the effects of opioids.   
 7. Important social, occupational or recreational activities are given up or reduced because of opioid use.  
 8. Re
current opioid use in situations in which it is physi cally hazardous  
 9. Continued use despite knowledge of having a persistent or recurrent physical or psychological problem t
hat is likely to have been caused or exacerbated by opioids.   
 *10.  Tolerance, as defined by either of the following:  
  (a) a  n
eed for markedly increased amounts of opioids to achieve intoxication or desired effect  
  (b) markedly diminished effect with continued use of the same amount of an opioid  
 *11.  Withdrawal, as manifested by either of the following:  
  (a) the characteristic opioid withdrawal syndrome  
  (b) the same (or a closely related) substance are taken to relieve or avoid withdrawal symptoms  
 * This criterion is not considered to be met for those individuals taking opioids solely under appropriate 
medical supervision.  
 
Severity:   
Mild: presence of 2- 3 symptoms  
Moderate: presence of 4- 5 symptoms  
Severe: presence of 6 or more symptoms.   
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  40 (48) 
 
APPENDIX C : QUICK INVENTORY OF D EPRESSION SYMPTOMS, SELF -REPORT  
 
CHECK THE ONE RESPONSE TO EACH ITEM THAT BEST DESCRIBES YOU FOR THE PAST SEVEN DAYS.  
 During the past seven days...  
 1. Falling Asleep:  
 0 - I never take longer than 30 minutes to fall asleep.  
1 - I take at least 30 minutes to fall asleep, less than half the time.  
2 - I take at least 30 minutes to fall asleep, more than half the time.  
3 - I take more than 60 minutes to fall asleep, more than half the time.  
 2. Sleep During the Night:  
 0 - I do not wake up at night.  
1 - I have a restless, light sleep with a few brief awakenings each night.  
2 - I wake u p at least once a night, but I go back to sleep easily.  
3 - I awaken more than once a night and stay awake for 20 minutes or more, more than half the time.  
 
3. Waking Up Too Early:  
 
0 - Most of the time, I awaken no more than 30 minutes before I need to get up.  
1 - More than half the time, I awaken more than 30 minutes before I need to get up.  
2 - I almost always awaken at least one hour or so before I need to, but I go back to sleep eventually.  
3 - I awaken at least one hour before I need to, and can't go back to sleep. 
 4. Sleeping Too Much:  
 0 - I sleep no longer than 7 -8 hours/night, without napping during the day.  
1 - I sleep no longer than 10 hours in a 24 -hour period including naps.  
2 - I sleep no longer than 12 hours in a 24 -hour period including naps.  
3 - I sleep longer than 12 hours in a 24 -hour period including naps.  
 5. Feeling Sad:  
 0 - I do not feel sad.  
1 - I feel sad less than half the time.  
2 - I feel sad more than half the time.  
3 - I feel sad nearly all of the time.  
  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  41 (48) 
 
 ___________________________________________________  
 
Please complete either 6 or 7 (not both)  
 6. Decreased Appetite:  
 0 - There is no change in my usual appetite.  
1 - I eat somewhat less often or lesser amounts of food than usual.  
2 - I eat much less than usual and only with personal effort.  
3 - I rarely eat within a 24 -hour period, and only with extreme personal effort or when others persuade me to 
eat. 
 - OR ‚Äì 
 7. Increased Appetite:  
 0 - There is no change from my usual appetite.  
1 - I feel a need to eat more frequently than usual.  
2 - I regularly eat more often and/or greater amounts of food than usual.  
3 - I feel driven to overeat both at mealtime and between meals.  
 ___________________________________________________  
 Please complete either 8 or 9 (not both)  
 8. Decreased Weight (within the last two weeks):  
 0 - I have not had a change in my weight.  
1 - I feel as if I  have had a slight weight loss.  
2 - I have lost 2 pounds or more.  
3 - I have lost 5 pounds or more.  
 - OR ‚Äì 
 9. Increased Weight (within the last two weeks):  
 
0 - I have not had a change in my weight.  
1 - I feel as if I have had a slight weight gain.  
2 - I have gained 2 pounds or more.  
3 - I have gained 5 pounds or more.  
 ___________________________________________________  
 
During the past seven days...  
 10. Concentration / Decision Making:  
 
0 - There is no change in my usual capacity to concentrate or make decisions.  
1 - I occasionally feel indecisive or find that my attention wanders.  
2 - Most of the time, I struggle to focus my attention or to make decisions.  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  42 (48) 
 
3 - I cannot concentrate well enough to read or cannot make even minor decisions.  
 
11. View of Myself:  
 0 - I see myself as equally worthwhile and deserving as other people.  
1 - I am more self-blaming than usual.  
2 - I largely believe that I cause problems for others.  
3 - I think almost constantly about major and minor defects in myself.  
 12. Thoughts of Death or Suicide:  
 0 - I do not think of suici de or death.  
1 - I feel that life is empty or wonder if it's worth living.  
2 - I think of suicide or death several times a week for several minutes.  
3 - I think of suicide or death several times a day in some detail, or I have made specific plans for suicide or have 
actually tried to take my life.  
 13. General Interest:  
 0 - There is no change from usual in how interested I am in other people or activities.  
1 - I notice that I am less interested in people or activities.  
2 - I find I have interest in only one or two of my formerly pursued activities.  
3 ‚Äì I have virtually no interest in formerly pursued activities.  
 14. Energy Level: 
 
0 - There is no change in my usual level of energy.  
1 - I get tired more easily than usual.  
2 - I have to make a big effort to start or finish my usual daily activities (for example, shopping, homework, 
cooking, or going to work).  
3 - I really cannot carry out most of my usual daily activities because I just don't have the energy.  
 15. Feeling Slowed Down:  
 0 - I think, speak, and  move at my usual rate of speed.  
1 - I find that my thinking is slowed down or my voice sounds dull or flat.  
2 - It takes me several seconds to respond to most questions and I'm sure my thinking is slowed.  
3 - I am often unable to respond to questions with out extreme effort.  
 16. Feeling Restless:  
 0 - I do not feel restless.  
1 - I'm often fidgety, wringing my hands, or need to shift how I am sitting.  
2 - I have impulses to move about and am quite restless.  
3 - At times, I am unable to stay seated and need to pace around.  
  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  43 (48) 
 
 
Scoring:  
 
Total QIDS scores range : 0 to 27  
‚Ä¢ No depression : ‚â§ 5 
‚Ä¢ Mild depression: 6 to 10 
‚Ä¢ Moderate depression : 11 to 15 
‚Ä¢ Severe depression : 16 to 20 
‚Ä¢ Very severe depression : ‚â• 21 
 
Clinical stud y protocol  OXD01 -001   
 
Version: 1.0, 19 April 2021  44 (48) 
 
 
APPENDIX  D: TIMELINE FOLLOWBACK METHOD ‚Äì DRUGS AND ALCOHOL  
 
 
 
To help us evaluate your drug and alcohol use, we need to get an idea of what your use was like in the past days. To do this, we would like you to fill out the attached calendar.  
 
ÔÉº Filling out the calendar is not  hard! 
ÔÉº Try to be as accurate as  possible. 
ÔÉº We recognize you won‚Äôt have perfect recall. That‚Äôs  OKAY. 
 
ÔÉº WHAT TO FILL  IN 
‚Ä¢ The idea is that for each day on the calendar we want you to indicate whether you ‚Äúused"  or ‚Äúdid not use ‚Äù 
 drugs  or alcohol . Specifically indicate whether you have used any of the following:  amphetamines (uppers), barbiturates, 
benzodiazepines (for example , Xanax, Ativan, Valium), cocaine, marijuana, methadone, opiates (for example, oxycodone, 
hydrocodone), phencyclidine (PCP) , or alcohol in any form . 
‚Ä¢ On days when you did not use drugs  or alcohol , you should write a ‚Äú0‚Äù in the  box. 
‚Ä¢ On days when you did use drugs  or alcohol , you should put a ‚ÄúÔÉº‚Äù in the  box for drugs or alcohol . 
 
It‚Äôs important that something is written for every  day for both drugs and alcohol , even if it is a ‚Äú0‚Äù.  
 
ÔÉº YOUR BEST ESTIMATE  
‚Ä¢ We realize it isn‚Äôt easy to recall things with 100%  accuracy.  
‚Ä¢ If you are not sure  whether  you used  a certain  drug  or alcohol  on a Thursday or a Friday  of a certain  week,  give it  your 
best guess ! The goal is to get a picture of how many days you were using drugs and your patterns of use.  
 
ÔÉº HELPFUL HINTS  
‚Ä¢ Holidays such as Thanksgiving and Christmas are marked on the calendar to help you better recall your  
use. Also, think about whether you used drugs  or alcohol  on personal holidays and events such as 
birthdays, vacations, or  parties.  
‚Ä¢ If you have regular drug or alcohol use patterns you can use these to help you recall your use. For 
example, you  may have weekend/weekday changes in your drug use or your drug use may be 
different depending where you are or whom you are  with.  
 
ÔÉº COMPLETING THE CALENDAR  
‚Ä¢ A blank calendar is attached. Each day should contain a "0" for no drug use or a " ÔÉº" for drug  and alcohol use . 
‚Ä¢ The time period we are talking about on the calendar  is 
from ___________________ to ___________________ .  
‚Ä¢ In estimating your drug use, be as accurate as  possible.   
Instructions for Filling Out the Timeline Drug  and Alcohol  Use Calendar  
Clinical stud y protocol  OXD01 -001   
 
Version: 1.0, 19 April 2021  45 (48) 
 
 
‚Ä¢ DOUBLE CHECK THAT ALL DAYS ARE FILLED IN BEFORE RETURNING THE CALENDAR.  
‚Ä¢ Before you start look at the SAMPLE CALENDAR below. 
 
ÔõôSobell, L. C. & Sobell, M. B., 2000 
 
 
ÔÉº SAMPLE CALENDAR  SEPTEMBER  3-9 
 
2000 SUN MON TUES  WED  THURS  FRI SAT  
 1 
 2 
 
 
S 3 
Drugs 0 
Alcohol 0  4 Labor Day  
Drugs 0 
Alcohol 0  5 
Drugs 0  
Alcohol ÔÉº 6 
Drugs 0  
Alcohol ÔÉº 7 
Drugs ÔÉº 
Alcohol ÔÉº 8 
Drugs 0  
Alcohol 0  9 
Drugs 0  
Alcohol 0 
E 10 
 
 11 
 12 
 13 
 14 
 15 
 16 
 
P 17 
 
 18 
 19 
 20 
 21 
 22 
 23 
 
 
T 24 
 25 
 26 
 27 
 28 
 29 
 30 
 
 
 
 
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  46 (48) 
 
 
APPENDIX E : TIMELINE FOLLOWBACK METHOD ‚Äì DRUGS 
 
 
 
To help us evaluate your drug use, we need to get an idea of what your use was like in the past days. To do this, we would like you to fill out the attached calendar.  
 
ÔÉº Filling out the calendar is not  hard! 
ÔÉº Try to be as accurate as  possible. 
ÔÉº We recognize you won‚Äôt have perfect recall. That‚Äôs  OKAY. 
 
ÔÉº WHAT TO FILL  IN 
‚Ä¢ The idea is that for each day on the calendar we want you to indicate whether you ‚Äúused"  or ‚Äúdid not use ‚Äù 
drugs. Specifically indicate  whether you have used any of the following: amphetamines (uppers), barbiturates, 
benzodiazepines (for example, Xanax, Ativan, Valium), cocaine, marijuana, methadone, opiates (for example, 
oxycodone, hydrocodone), phencyclidine (PCP).  
‚Ä¢ On days when you did not use drugs , you should write a ‚Äú0‚Äù in the  box. 
‚Ä¢ On days when you did use drugs , you should put a ‚ÄúÔÉº‚Äù in the  box. 
 
It‚Äôs important that something is written for every  day, even if it is a ‚Äú0‚Äù.  
 
ÔÉº YOUR BEST ESTIMATE  
‚Ä¢ We realize it isn‚Äôt easy to recall things with 100%  accuracy.  
‚Ä¢ If you are not sure  whether  you used  a certain  drug  on a Thursday or a Friday  of a certain  week,  give  it  
your  best  guess! The goal  is to get a picture  of how  many  days  you were using  drugs  and your  patterns  
of use. 
 
ÔÉº HELPFUL HINTS  
‚Ä¢ Holidays such as Thanksgiving and Christmas are marked on the calendar to help you better recall your  
use. Also, think about whether you used drugs on personal holidays and events such as birthdays, 
vacations, or  parties.  
‚Ä¢ If you have regular drug use patte rns you can use these to help you recall your use. For example, you  
may have weekend/weekday changes in your drug use or your drug use may be different depending 
where you are or whom you are with.  
 
ÔÉº COMPLETING THE CALENDAR  
‚Ä¢ A blank calendar is attached. Eac h day should contain a "0" for no drug use or a " ÔÉº" for drug  use. 
‚Ä¢ The time period we are talking about on the calendar  is 
from ___________________ to ___________________ .   
Instructions for Filling Out the Timeline Drug Use Calendar  
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  47 (48) 
 
 
‚Ä¢ In estimating your drug use, be as accurate as  possible.  
‚Ä¢ DOUBLE CHECK THAT ALL DAYS ARE FILLED IN BEFORE RETURNING THE CALENDAR.  
‚Ä¢ Before you start look at the SAMPLE CALENDAR below.  
 
ÔõôSobell, L. C. & Sobell, M. B., 2000 
 
 
ÔÉº SAMPLE CALENDAR SEPTEMBER 3 -9 
 
2000  SUN MON TUES  WED  THURS  FRI SAT  
 1 
 2 
 
 
S 3 
Drugs 0  
 4 Labor Day  
Drugs ÔÉº 
 5 
Drugs  0 
 6 
Drugs 0  
 7 
Drugs ÔÉº 
 8 
Drugs 0  
 9 
Drugs 0  
 
E 10 
 
 11 
 12 
 13 
 14 
 15 
 16 
 
P 17 
 
 18 
 19 
 20 
 21 
 22 
 23 
 
 
T 24 
 25 
 26 
 27 
 28 
 29 
 30 
 
 
 
 
 
Clinical study protocol OXD01 -001   
 
Version: 1.0, 19 April 2021  48 (48) 
 
 
APPENDIX F: VISUAL ANALOG SCALE ‚Äì OPIOID CRAVINGS  
 Please  draw a perpendicular mark through the line between No Cravings and The Worst Possible Cravings to 
describe the intensity of your opioid cravings  in the last 24 hours.  
   
No cravings   The worst 
possible cravings   
 